A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514
Status:
Not yet recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Oncocross is developing OC514, a drug-drug combination product containing 2 active
pharmaceutical ingredients for cancer cachexia. This study is designed to assess the safety
and tolerability of single and multiple oral doses of OC514 in healthy adult volunteers.